


WEEKS






FIGURE 7

12/26 FIGURE 8A-1





FIGURE 8A-2





13/26 FIGURE 8B

Resorcinol Uninhibited With GD2 With GM2


A B A B A B A B A B


14/26






16/26







18/26 FIGURE 10A




19/26 FIGURE 10B




20/26





21/26




22/26 FIGURE 12







V ...



.p=.006 Patients with pretreatment GM2 antibody, deleted Multiple positive nodes, 34 pts 9 Treated with GM2/BCG: Single positive node, 23 pts o Treated with BCG: Single positive node, 25 pts △ Multiple positive nodes, 34 pts ▲ 54 48 42 36 FIGURE 16 36 24 48 12 9 0.0 0.2 0.1 0.4 0.3 0.8 0.0 0.5 0.8 Proportion Disease Free

26/26

Months after Surgery